Although tumor-associated macrophages have been extensively studied in the control of response to radiotherapy, the molecular mechanisms involved in the ionizing radiation-mediated activation of macrophages remain elusive. Here we show that ionizing radiation induces the expression of interferon regulatory factor 5 (IRF5) promoting thus macrophage activation toward a proinflammatory phenotype. We reveal that the activation of the ataxia telangiectasia mutated (ATM) kinase is required for ionizing radiation-elicited macrophage activation, but also for macrophage reprogramming after treatments with γ-interferon, lipopolysaccharide or chemotherapeutic agent (such as cisplatin), underscoring the fact that the kinase ATM plays a central role during macrophage phenotypic switching toward a pro-inflammatory phenotype through the regulation of mRNA level and post-translational modifications of IRF5. We further demonstrate that NADPH oxidase 2 (NOX2)-dependent ROS production is upstream to ATM activation and is essential during this process. We also report that the inhibition of any component of this signaling pathway (NOX2, ROS and ATM) impairs pro-inflammatory activation of macrophages and predicts a poor tumor response to preoperative radiotherapy in locally advanced rectal cancer. Altogether, our results identify a novel signaling pathway involved in macrophage activation that may enhance the effectiveness of radiotherapy through the reprogramming of tumor-infiltrating macrophages.
Approximately, half of all cancer patients are treated with radiotherapy alone or in combination with chemotherapy. Although ionizing radiation (IR) directly causes senescence and death of tumor cells through the generation of reactive oxygen species (ROS) and DNA damage, 1 recent studies underscore the fact that IR can also modulate immune cell functions and favor consequently the development of anticancer immunity. 2, 3 IR can induce the exposure of 'eat-me' signals (such as calreticulin) and the release of danger signals (such as ATP and HMGB1) by the irradiated dying tumor cells (also referred as immunogenic cell death), 4 thus contributing to specific T-cell response by increasing the tumor antigen cross-presentation to dendritic cells 5 and/or modifying the immunosuppressive microenvironment of tumors. 6, 7 IR can also control tumor immune response through the direct modulation of innate immune cell functions. Treatment with IR can modulate Langerhans cell functions and induce the accumulation of regulatory T cells into tumors. 8 In addition, IR controls macrophage plasticity and programs tumorassociated macrophages (TAMs) toward a pro-inflammatory phenotype that orchestrates specific tumor immune response. 9 However, microenvironment factors such as hypoxia may affect this IR-responsive macrophage activation program by favoring a pro-tumorigenic activation phenotype that is associated with tumor resistance. 10 Nevertheless, the molecular mechanisms underlying IR-induced macrophage activation remain elusive.
TAMs represent a major cellular component of the tumor microenvironment. 11 These macrophages derive from blood monocytes that, after their recruitment into tumors, differentiate and are activated in response to different environmental signals. Macrophages can be broadly classified as classically activated pro-inflammatory macrophages and alternatively activated protumorigenic macrophages. 12 The interferon regulatory factor 5 (IRF5) was demonstrated to determine the pro-inflammatory macrophage phenotype [13] [14] [15] along with other transcription factors (such as STAT1 and NF-κB), whereas IRF4, 16 STAT6 17 and KLF4 18 are key transcription factors required for the protumorigenic macrophage phenotype. Interferon gamma plus lipopolysaccharide (LPS) or tumor necrosis factor α alone are known to induce classical macrophage activation that is characterized by an increased secretion of pro-inflammatory cytokines and chemokines (such as interleukin (IL)-1β), an augmented production of inducible nitric oxide synthase (iNOS) 19 and of ROS. 12 Conversely, glucocorticoids, IL-4/IL-13 and IL-10 drive macrophages toward the alternative activation program with a reduced production of pro-inflammatory cytokines but a higher level of anti-inflammatory IL-10, TGF-β, arginase, membrane scavenger and mannose receptors. Pro-inflammatory macrophages possess bactericidal and anti-tumoral activities, while pro-tumorigenic macrophages are associated with immune regulatory and tissue repair activities, highlighting the diversity of macrophage functions. In response to tumor microenvironment signals (such as hypoxia and tumor-derived lactate 20, 21 ), TAMs mainly adopt a pro-tumorigenic phenotype that contributes to tumor progression by promoting tumor growth, metastasis, angiogenesis and by suppressing immune responses. [22] [23] [24] In addition, several studies have demonstrated that TAMs are also associated with treatment resistance and poor clinical outcomes in various cancer settings (such as lymphoma, melanoma, sarcomas and lung cancer [25] [26] [27] [28] ), making them attractive targets for the development of new anticancer strategies. 29, 30 In this context, a better understanding of the molecular basis of the IRmediated macrophage activation is needed for the improvement of the efficacy of radiotherapy. In this study, we explored the molecular mechanisms involved in IR-induced macrophage reprogramming.
Results
Cell-autonomous activation of macrophages after ionizing radiation. Considering that immune cells may influence the functional reprogramming of macrophages, 29 we first analyzed IR-mediated macrophage activation using human colon tumor xenografts in immunodeficient mice. HCT116 cells were subcutaneously inoculated into the right flanks of athymic nude mice. Seven days after inoculation, the irradiation of the palpable tumor mass with a single dose of 20 Gy resulted in significant tumor growth inhibition, as compared to the controls (Figure 1a ). After 29 days, the residual irradiated tumors did not show any increase of the density of CD11b + macrophages (Supplementary Figure 1a) , but revealed an increased frequency of CD11b + macrophages that expressed iNOS (iNOS /pro-inflammatory phenotype macrophages in irradiated tumors is required for the modification of tumor microenvironment and tumor regression. Of note, previous reports characterized this process in conditions of relatively low-dose IR (2 Gy) exposure. 6, 9 Our observation that TAMs exhibited an increased phosphorylation of the histone variant H2AX (also known as γ-H2AX) on serine 139 (Figures 1d and e) underlined an unsuspected link between DNA damage response and macrophage activation. To check the possibility whether IR can directly target and activate macrophages, we irradiated human THP1 macrophages with a single dose of 2 Gy and analyzed, by fluorescence microscopy and flow cytometry, the expression levels of iNOS and γ-H2AX. The increase in iNOS and γ-H2AX expression levels in irradiated THP1 macrophages (Figures 1f-h, Supplementary Figures 1b and 1c) revealed that IR could directly target macrophages to promote their activation toward a pro-inflammatory phenotype. We then analyzed by immunoblot the expression of a central transcription factor involved in macrophage activation, the IRF5 15 and observed that after single radiation doses of 2 and 4 Gy, phorbol-12-myristate-13-acetate (PMA)-differentiated human THP1 macrophages (Figure 1i ), human primary monocyte-derived macrophages (hMDM) (Figure 1j ) and murine RAW264.7 macrophages (Figure 1k ) exhibited an enhanced expression of IRF5 (Figures 1i-k) . In addition, through immunoprecipitation experiments, we observed that after 2 Gy irradiation of RAW264.7 macrophages the proinflammatory transcription factor IRF5 was phosphorylated on serine ( Figure 1l ). We also demonstrated that after, respectively, 96 and 12 h of irradiation, hMDM ( Figure 1m ) and murine RAW264.7 macrophages (Figure 1n ) released two pro-inflammatory cytokines IL-1β and IL-8. To further complete the cytokine profile analysis, we determined the transcription levels of pro-and anti-inflammatory cytokines and observed increased mRNA expression of proinflammatory cytokines (such as TNF-α, IFN-γ, IL-6 or IL-23) in 2 Gy-irradiated PMA-differentiated human THP1 macrophages (Figures 1o-r) and detected an increased secretion of pro-inflammatory cytokines by 4 Gy-irradiated hMDM (including TNF-α, IFN-γ, IL-6 and IL-8) as compared with controls (Figures 1s, t and Supplementary Figures 1d-1g) . Altogether, these results indicate that IR can promote a cell-autonomous activation of macrophages toward a pro-inflammatory phenotype.
ATM-mediated DNA damage response regulates the transcription of IRF5 in response to ionizing radiation. To further characterize the molecular mechanisms involved in IR-elicited macrophage activation, we first studied the induction of DNA damage-associated signaling pathways. Fifteen minutes after single radiation dose of 2 Gy, PMAdifferentiated human THP1 macrophages (Figures 2a-c) exhibited a strong nuclear accumulation of γ-H2AX + foci (Figures 2a and b) and of 53BP1 + foci (Figures 2a and c ) that could still be detected 6 h after exposure (Figures 2b and c) , revealing the fact that DNA double-strand breaks are produced in response to IR. One hour after single radiation dose of 2 Gy, murine RAW264.7 macrophages also displayed increased γ-H2AX + foci (Figures 2d and e) . Considering that the kinase ATM (mutated in the inherited recessive autosomal disease ataxia telangiectasia) is the major kinase involved in the phosphorylation of H2AX (on serine 139), 31 we evaluated the role of ATM in the activation of macrophages in response to IR. We observed that the vast majority of 2 Gy-irradiated murine RAW264.7 macrophages exhibited the activating auto-phosphorylation of ATM on serine 1981 (ATMS1918*) 1-h post irradiation (Figures 2d and f) . These results that were confirmed by immunoblots (Figures 2g and h ) and flow cytometry (Supplementary Figure 2a) revealed also the positive correlation between ATMS1981* and IRF5 expression when hMDM (Figure 2g ) or murine RAW264.7 macrophages ( Figure 2h ) were irradiated with single doses of 2, 4 and 8 Gy. In addition, we detected an increase of ATMS1981* in CD68 + macrophages that were found in tumor samples after radiotherapy of rectal cancer patients (Figures 2i and j) , as compared to unirradiated patients. The ATMS1918* phosphorylation was positively correlated with the increased frequencies of tumor-associated iNOS +
CD68
+ macrophages that have been detected 6 weeks after radiotherapy The kinase ATM dictates classical macrophage activation. In order to check whether the activation of ATM was a common feature of various pro-inflammatory macrophage activation programs, we analyzed the presence of DNA damage-associated nuclear foci in response to classical macrophage activators. 32 Using confocal microscopy, we detected an accumulation of ATMS1981* + and γ-H2AX + foci in the nuclei of murine RAW264.7 macrophages that were treated for 24 h with recombinant murine IFN-γ (mIFN-γ) or LPS (Figures 3a-c) . Using immunoblots, we also observed that the activation of ATM was concomitant with an increased expression of IRF5 in the PMA-differentiated THP1 macrophages (Figures 3d and f) (Figure 3i) ) or modulators of DNA repair (such as Olaparib (Figure 3j) ), not only activated ATM but also increased IRF5 expression (Figures 3g-j) . The results that are observed in absence of macrophage cytotoxicity (Supplementary Figure 3a) suggest that the DNA damage response signaling pathway might be a common pathway involved in classical macrophage activation. Moreover, we demonstrated that the pharmacological inhibition (Figures 3k and l) and the specific depletion (Figures 3m and n) of ATM inhibited the increase of IRF5 expression that we previously detected after the treatment of PMA-differentiated THP1 macrophages (Figure 3k Figure 3b) , confirming the essential role of the kinase ATM in classical macrophage activation.
ROS production induces ATMS1981* phosphorylation and IRF5 expression during macrophage activation. Considering that ROS have been involved in both ATM activation and macrophage differentiation, 33, 34 we investigated the role of ROS production during macrophage activation. Using flow cytometry to detect the conversion of the 2,7-dichlorohydro fluorescein diacetate (H 2 DCFDA) into 2,7-dichlorohydro fluorescein (DCF) when ROS are produced, we evaluated the ability of murine RAW264.7 macrophages to generate ROS following IR or mIFN-γ treatment and revealed that both these treatments induced ROS production (Figures 4a-d) . Importantly, we demonstrated that the N-acetyl cysteine (NAC) and the superoxide dismutase (SOD) mimetic Mn(III)tetrakis (4-benzoic acid) (MnTBAP) that blunted the ROS production (Figures 4a-d) , inhibited also ATMS1981* (Figures 4e-g ) and reduced the increased expression of IRF5 (Figures 4e-g ) that we observed after treatment with IR (Figures 4e and g ) or mIFN-γ (Figure 4f + nuclear foci and ATMS1981* + macrophages are shown in inserts (scale bar, 5 μm). Results are expressed as mean value ± S.E.M. P-values (*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001) were calculated using unpaired Student's t-test. (g, h) ATMS1981*, ATM and IRF5 expression after, respectively, 96 and 6 h culture of hMDM (g) or murine RAW264.7 macrophages (h) that have been irradiated (or not) with indicated doses are determined. Representative immunoblots are shown. Actin is used as loading control. (i-l) Representative confocal micrographs and frequencies of ATMS1981* + CD68 + (i, j) or iNOS + CD68 + (k, l) macrophages that have been detected in absence or after 45 Gy total dose of fractionated irradiation on tumor samples obtained from locally advanced rectal cancer patients are shown (scale bar, 20 μm; scale bar of insert, 5 μm). Results are expressed as mean value ± S.E.M. P-value (*Po0.05) was calculated using Mann-Whitney U-test. (m, n) ATMS1981*, ATM and IRF5 expression after, respectively, 6 and 96 h culture of murine RAW264.7 macrophages that have been depleted for ATM (m) or hMDM that have been treated with 20 μM of KU55933 (n) and irradiated (or not) with 2 Gy (m) or 4 Gy (n) are shown. Representative immunoblots are shown. GAPDH (or actin) is used as loading control. (o) ATMS1981*, ATM and IRF5 expression after 6 h culture of murine RAW264.7 macrophages that have been treated with 10 μM of Olaparib and irradiated (or not) with 2 Gy are shown. Representative immunoblots are shown. GAPDH is used as loading control. (p) IRF5 mRNA expression on PMA-differentiated human THP1 macrophages that have been depleted for ATM and irradiated (or not) with 2 Gy was determined by quantitative real-time PCR. Results are expressed as mean value ± S.E.M. and represented as fold change as compared to controls. P-values (***Po0.001 and ****Po0.0001) were calculated using one-way ANOVA test. Quantification of western blot bands are shown in Supplementary Figure 4 viability ( Supplementary Figures 3c and 3d) . Altogether, these results indicate that by controlling the phosphorylation of ATM and the induction of the IRF5, ROS produced in the stimulated macrophages play a key role in the activation process.
The NADPH oxidase 2 is responsible for ROS production and ATM phosphorylation during macrophage activation. The NADPH oxidases are major regulated sources of ROS generation. 35, 36 To characterize mechanisms that are involved in ROS generation during macrophage activation, Results are expressed as mean value ± S.E.M. P-values (*Po0.05, **Po0.01, ***Po0.001) were calculated using unpaired Student's ttest. (d-i) ATMS1981*, ATM and IRF5 expressions after 24 h culture of PMA-differentiated human THP1 macrophages (d, f, g) or murine RAW264.7 macrophages (e, h, i) that have been treated (or not) with 20 ng/ml of recombinant human IFN-γ (IFN-γ) (d), 20 ng/ml of recombinant murine IFN-γ (mIFN-γ) (e), 100 ng/ml of LPS (f), 10 μM of CDDP (g, h) or 200 ng/ml of neocarzinostatin (NCZ) (i) are determined. Representative immunoblots are shown. GAPDH is used as loading control. (j-n) ATMS1981*, ATM and IRF5 expressions after, respectively, 24 h culture of murine RAW264.7 macrophages (j, l, m), PMA-differentiated human THP1 macrophages (κ) or hMDMs (n) that have been incubated with 10 μM of Olaparib (j), with 20 μM of KU55933 (k, l) or depleted for ATM (m, n) and treated (or not) with 20 ng/ml mIFN-γ (for RAW264.7 macrophages) (j, l, m), 20 ng/ml human IFN-γ (for PMA-differentiated human THP1 macrophages) (κ) or 4 μg/ml of human IFN-γ (for hMDM) (n) are evaluated. Representative immunoblots are shown. Actin (or GAPDH) is used as loading control. Quantification of western blot bands is shown in Supplementary Figure 4 we examined the role of NADPH oxidase 2 (NOX2), which is mainly expressed in macrophages and neutrophils. 35, 36 First, using immunoblots, we observed that NOX2 was upregulated after irradiation of PMA-differentiated THP1 macrophages (Figure 5a ) with single doses of 2 and 4 Gy. These results were confirmed with the treatments of hMDM (Figure 5b (Figure 5d ). NOX2 expression was also found increased in CD68 + macrophages that were detected in tumor samples obtained 6 weeks after radiotherapy of rectal cancer patients (Figures 5f and g ), as compared to biopsies obtained from the same patients before radiotherapy. Then, we evaluated the effect of the pharmacological NADPH oxidase inhibitor, diphenylene iodonium (DPI) on ROS production, ATMS1981* and IRF5 upregulation detected after the treatment of RAW264.7 macrophages with IR ( Figures 5h, i and l) or mIFN-γ (Figures 5j, k and m) . We demonstrated that DPI impaired all events of the abovedescribed signaling cascade (Figures 5h-m) without modifying macrophage viability (Supplementary Figures 3e and 3f ). In addition, as revealed by immunoblots, the depletion of NOX2 with specific small interfering RNA in irradiated (Figure 5n and Supplementary Figure 3g) or mIFN-γ-treated (Figure 5o and Supplementary Figure 3h) RAW264.7 macrophages reduced also ATMS1981* and IRF5 upregulation, in comparison to control cells. These results demonstrate that the induction of NOX2-dependent ATM activation is required for tuning macrophages toward a pro-inflammatory phenotype.
The alteration of NOX2-dependent tumor macrophage activation is associated with poor prognosis after radiotherapy. Despite the fact that neoadjuvant chemoradiotherapy for locally advanced rectal cancer patients improve the local control of the tumors, only 15% of patients exhibit a complete response to treatment. 37 In this context, we determined whether the perturbation of the signaling pathway that we involved in the macrophage activation toward a pro-inflammatory phenotype might be associated with the absence of local response to radiotherapy. We analyzed resected specimens of rectal cancer patients obtained after neoadjuvant radiotherapy performed before radical tumor resection. According to the tumor regression grade (TRG) criteria, these patients were classified into 'good responders' (TRG ⩽ 2, n = 29) and 'bad responders' (TRG ⩾ 3, n = 27) (Supplementary Table 1 ). We analyzed the total number of CD68 + TAM in both groups of irradiated tumors, and did not detect a significant difference in the CD68 + TAMs infiltration (Figure 6a ). In addition, we also detected the autophosphorylation ATMS1981* in~20% of TAMs (Figure 6b ), but we did not observe a significant difference for the frequencies of TAMs exhibiting ATMS1981* (ATMS1981* + CD68 + ) between the two groups of tumors (Figure 6c) . Interestingly, we detected a significant increase in the frequency of TAMs revealing an enhanced expression of iNOS (iNOS + CD68 + ) in tumor samples obtained from 'good responders' as compared to those obtained from 'bad responders' (Figures 6d and e) , confirming that macrophage activation toward a pro-inflammatory phenotype is associated with the local tumor control. Finally, we found a higher frequency of TAMs showing an upregulation of (Figures 6f and g ), revealing that the detection of NOX2 expression on TAMs may serve as a predictive factor for radiotherapy effectiveness. Multivariate statistical analysis confirmed these results (Table 1) . Altogether, these results confirm that the NOX2 → ROS → ATMS1981* cascade may contribute to an efficient macrophage activation in response to radiotherapy.
Discussion
Phenotypic and functional plasticity are key features of immune cells. 38 TAMs display a mixed functional phenotype with a majority of alternative features 39 that have been associated with tumor growth and resistance to anticancer therapies. Although reprogramming TAMs represents a promising approach to enhance cancer therapies, [40] [41] [42] [43] [44] molecular mechanisms underlying IRelicited macrophage activation have been poorly characterized. In this paper, we showed that the in vitro treatment of macrophages with various doses of IR led to their activation toward a pro-inflammatory phenotype. Our observations were confirmed using xenograft tumor models and human rectal cancer specimens obtained from patients that have been treated with chemoradiotherapy. Consistent with other in vitro and in vivo studies, 13, 15, 45, 46 our results revealed that the transcription factor IRF5, which is the major regulator of proinflammatory macrophage phenotype, 15 is activated in response to IR (as revealed by the upregulated expressions of IRF5-and IRF5-dependent target genes (such as IL-6, TNF-α or IFN-γ)). IRF5, which is involved in the regulation of the expression of pro-inflammatory cytokine genes and in the repression of anti-inflammatory cytokine genes (such as IL-10), 15, 47 plays also a central role in hematopoietic cell development 48 and in the susceptibility to inflammatory autoimmune diseases (such as systematic lupus erythematosus, rheumatoid arthritis and multiple sclerosis), [49] [50] [51] demonstrating that the expression of IRF5 is tightly regulated during macrophage homeostasis.
Considering that IR mainly acts through the induction of DNA damages and the production of ROS, 52, 53 we then investigated the role of DNA damage response and ROS production during this process. In this paper, we initially reported that the DNA damage/repair kinase ATM is activated by IR and by classical macrophage activators (such as LPS and IFN-γ), and that DNA damage/repair ATM kinase is required for macrophage activation. Despite the fact that the ATM kinase may contribute to the development of T cells 54 and of professional antigen-presenting cells (such as macrophage and dendritic cells) 55, 56 and modulate functions of immune cells (such as STING-dependent macrophage production of type I IFNs 57 ), the contribution of ATM to macrophage activation was never investigated. Here, we found that IR induced the phosphorylation of ATM (on serine 1981) and of 58 ) have already been involved in monocyte/macrophage development and functions, the cellular events and signaling pathways that lead to ATM activation and control IRF5 expression during macrophage activation were until now never characterized.
In this study, we also identified the NOX2-dependent ROS production as an upstream second messenger required for ATM phosphorylation and macrophage activation. We found that the expression of NOX2 was increased after IR or IFN-γ treatment. The increased NOX2 expression that we detected both in vitro and in 'good responders' to radiotherapy might be regulated at transcriptional level (through the activation of PU.1 or NF-κB transcription factors 35 ) or at post-transcriptional level. 35 Increased expression of NOX2 then led to the generation of ROS that contributes to double-strand breaks formation, induces the activation of ATM and IRF5, and favors the functional switch of macrophages from anti-inflammatory to pro-inflammatory phenotype (Figure 7 ). Although we demonstrated that NOX2 expression controlled macrophage activation after IR or IFN-γ stimulation, the precise mechanisms involved in NOX2 expression or linking DNA doublestand breaks formation, phosphorylation of ATM (ATMS1981*) and IRF5 expression are under active investigations. In this study, we also demonstrated that the histological detection of any components of the molecular cascade that we described in macrophages (NOX2 → ROS → ATMS1981* → IRF5) predicted the effectiveness of radiotherapy and might also help for the prediction of other anticancer treatments.
We also showed that the modulation of these components impacts the reprogramming of macrophages elicited by IR or IFN-γ. We found that ROS scavenging or inhibition of NOX2 or ATM activity interrupts this molecular cascade in vitro. Moreover, we did not detect the induction of this signaling pathway on tumor samples obtained from 'bad responders' as compared to those obtained from 'good responders'. More importantly, we demonstrated that modulators of DNA repair (such as Olaparib) that are currently evaluated in combination with radiotherapy triggered this signaling pathway and resulted in macrophage activation toward a pro-inflammatory phenotype. In this context, the stimulation of NOX2 activity, the enhanced generation of ROS, the inhibition of DNA repair, the activation of ATM or the transactivation of IRF5 could constitute effective strategies to enhance radiotherapy efficacy in clinic. Therefore, our results suggested that macrophage activation toward NOX2-/ATM-dependent proinflammatory phenotype was involved in the tumor response to chemoradiotherapy (with no impact on the overall survival and disease-free survival of patients). We propose that by combining radiotherapy with other modalities of cancer treatments (such as PARP inhibitors) might enhance the tumor response to radiotherapy and lead to a long-term benefit to rectal patients.
Materials and Methods
Cells and reagents. The human monocyte cell line THP1 cells and the murine macrophage-like RAW264.7 cells were maintained in RMPI-1640-Glutamax medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Hycultec GmbH, Beutelsbach, Germany) and 100 IU/ml penicillin-streptomycin (Life Technologies). To obtain THP1 macrophages, THP1 monocytes were differentiated with 320 nM of PMA (#tlrl-PMA, Invivogen, San Diego, CA, USA) during 24 h. Then, cells were washed three times to remove PMA and non-adherent cells. For the generation of hMDM, buffy coats from healthy donor blood were obtained from the French blood bank (Etablissement Français du Sang) under the control of convention with the INSERM. In accordance with French law, written informed consent for the use of cells for clinical research was obtained from each donor. Monocytes were obtained from buffy coats and were differentiated into macrophages by using human AB serum in macrophage medium, as previously described. 59 After 7-day differentiation, hMDM were harvested and suspended in macrophage medium containing 10% (vol/vol) heat-inactivated FBS, yielding from 91 to 96% of CD14-positive cells that expressed macrophage differentiation markers (C11b and CD71), and macrophage alternative activation markers (CD163). All cells were maintained under 5% CO 2 humidified atmosphere at 37°C. Dimethyl sulfoxide Figure 7 Proposed model for the roles of NOX2 and ATM activations in proinflammatory macrophage activation (DMSO, #D2650), LPS (#L2880), N-acetyl-L-cysteine (NAC, #A7250), diphenyleneiodonium chloride (DPI, D2926), NCZ (#N9162), cis-diammineplatinum(II) dichloride (cisplatin) (CDDP, #P4394) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Recombinant murine IFN-γ (mIFN-γ, ♯315 − 05) was obtained from PeproTech (Neuilly-sur-seine, France). Recombinant Human IFN-γ (IFN-γ, #285-IF/CF) was from R&D Systems (Minneapolis, MN, USA). KU55933 (#3544/10) was from Tocris Bioscience (Bristol, UK). Mn(III)tetrakis (Fontenay-sousbois, France) (4-benzoic acid) porphyrin chloride (MnTBAP, #475870) was from Calbiochem (San Diego, CA, USA). Olaparib (#S1060) was from Selleckchem (Houston, TX, USA). PMA (#tlrl-PMA) was from Invivogen.
Antibodies. Antibodies used for immunofluorescence were anti-phospho-ATM (Ser1981) (#ab36810), anti-iNOS (#3523) antibodies from Abcam (Cambridge, UK), anti-53BP1 (#4937) antibody from Cell Signaling Technology (Danvers, MA, USA), anti-phospho-H2AX (Ser139) (#05-636) antibody from EMD Millipore (Billerica, MA, USA). Antibodies used for immunoblots were anti-phospho-ATM (Ser1981) (10H11. E12) (#4526) and anti-ATM (D2E2) (#2873) antibodies from Cell Signaling Technology; anti-IRF5 (#ab21689), anti-phospho-serine (#ab9332) and anti-IL-1β (#ab2105) antibodies were from Abcam; anti-gp91-phox (54.1) (NOX2) (#sc-13054) antibody was from Santa Cruz (Dallas, TX, USA). Anti-GAPDH antibody (#MAB374, EMD Millipore) or anti-beta actin antibody (AC-15) (HRP) (#49900, Abcam) was used as a loading control. Phenotypic analyses on primary human MDMs were realized by flow cytometry using anti-CD14 (PE) (#12-1049-42, eBioscience, Illkrich, France), anti-CD11b (APC-Cy7) (#557657, BD Pharmingen, Le pont de Claix, France), anti-CD71 (PE) (#555537, BD Pharmingen, Le pont de Claix, France) and anti-CD163 (Alexa Fluor 647) (#562669, BD Pharmingen) antibodies. For immunohistochemistry staining, anti-mouse CD11b (Clone M1/70, #550282) antibody was purchased from BD Biosciences (Le pont de Claix, France); antiphospho-ATM (Ser1981) (EP1890Y, #GTX61739) antibody was from GeneTex (Irvine, CA, USA); anti-gp91-phox (54.1) (NOX2) antibody was from Santa Cruz (sc-130534, Dallas, TX, USA); anti-phospho-H2AX (Ser139) (#05-636) was from EMD Millipore, anti-iNOS (#ab3523) was from Abcam and anti-human CD68 antibodies were, respectively, from DAKO (Santa Clara, CA, USA) (#MO876) and Thermo Fischer Scientific (#PA5-32331, Illkrich, France).
Macrophage activation. Human MDM (10 6 ) were activated by treatment with 4 μg recombinant human IFN-γ for 24 h. THP1 monocytes were differentiated into macrophages by 320 nM PMA for 24 h. Then, macrophages were activated with 20 ng/ml recombinant human IFN-γ or 100 ng/ml LPS during 24 h. RAW264.7 macrophages were activated with 20 ng/ml recombinant murine IFN-γ or 100 ng/ml LPS for 24 h.
Irradiation. Cells were seeded in 6-well plates, 12-well plates or 25 cm 2 flasks and irradiated with gamma-ray irradiator IBL-637 (Cs 137 , 1 Gy/min, gamma CIS-BioInternational, IBA, Saclay, France) or with X-ray irradiator (1 Gy/min, X-RAD 320, Precision X-Ray). Cells were harvested at indicated time points (hMDMs and THP1 macrophages at 96 h, RAW264.7 macrophages at 6 h for cell lysates and 12 h for supernatants) after irradiation for subsequent experiments.
RNA-mediated interference. The SMARTpool siGENOME ATM siRNA (M-003201-04-0005) against ATM (siRNA ATM), SMARTpool siGENOME CYBB siRNA (M-011021-01-0005) against NOX2 (siRNA NOX2) and siGENOME NonTargeting siRNA Pool #1 (D-001206-13-05) as control were purchased from Dharmacon (Lafayette, CO, USA). siRNA-5 control, siRNA-4 and siRNA-5 against ATM were from Sigma-Aldrich. Sequences of siRNAs are as follows: SMARTpool siGENOME CYBB siRNAs (containing siRNA-1: 5′-GAAGACAACUGGACAGGAA-3′; siRNA-2: 5′-GGAACUGGGCUGUGAAUGA-3′; siRNA-3: 5′-GUGAAUGCCCGAGU CAAUA-3′ and siRNA-4: 5′-GAAACUACCUAAGAUAGCG-3′); SMARTpool siGEN-OME ATM siRNAs (containing siRNA-1: 5′-GCAAAGCCCUAGUAACAUA-3′; siRNA-2: 5′-GGGCAUUACGGGUGUUGAA-3′; siRNA-3: 5′-UCGCUUAGCAGGA GGUGUA-3′; siRNA-4: 5′-UGAUGAAGAGAGACGGAAU-3′); ATM siRNA-5 (5′-UG AAGUCCAUUGCUAAUCA-3′); ATM siRNA-6 (5′-AACAUACUACUCAAAGACA-3′) and control siRNA-5 (5′-UUCAAUAAAUUCUUGAGGU-3′). Sequences of ATM siRNA-5, ATM siRNA-6 and SMARTpool siGENOME CYBB siRNA (M-011021-01-0005) that we used are, respectively, perfectly aligned against mouse ATM or NOX2 genes. The control siGENOME Non-Targeting siRNAs were a pool of four on-target plus non-targeting siRNAs. INTERFERin Reagent (#409-10, Polyplus Transfection, Illkrich, France) was used as the siRNA transfection reagent for hMDM and PMA-differentiated THP1 macrophages according to the manufacturer's instructions.
Transfection of hMDM was performed as previously described. 59 Briefly, hMDM were seeded (2.5 × 10 5 hMDM/0.25 ml per well in 24-well plate in macrophages medium+10% FBS) and were allowed to adhere to the substrate by culturing at 37°C for 2 h prior to siRNAs transfection. siRNAs were pre-diluted in 125 μl of Opti-MEM (Thermo Fisher Scientific) in which 10 μl of INTERFERin were then added. The transfection mix was left to incubate at room temperature for 15 min and was added to hMDM to achieve the final concentration of 100 nM siRNAs. The MDMs were then incubated at 37°C for 24 h. The medium was replaced by fresh macrophage medium supplemented with 10% FBS before subsequent experiments. Lipofectamine RNAi max (#13778150, Life Technologies, Illkrich, France) was used to transfect RAW264.7 macrophages according to the manufacturer's instructions. Briefly, RAW264.7 cells were seeded (10 5 cells per ml per well in 12-well plate) and were allowed to adhere to the substrate by culturing at 37°C for 24 h prior to siRNAs transfection. The transfection mix was added to the final concentration of 10 nM siRNAs. The RAW264.7 cells were then incubated at 37°C for 24 h before subsequent experiments.
Immunofluorescence microscopy and flow cytometry. Cells were grown on coverslips and were treated as indicated. After treatment, cells were rinsed twice, fixed with 10% neutral buffered formalin (Sigma-Aldrich) for 10 min and then permeabilized with 0.3% Triton X-100 in PBS for 15 min. Cells were then washed twice with PBS and were blocked with 10% FBS in PBS for 1 h at room temperature, followed by incubation with primary antibodies in 10% FBS in PBS for 1 h at 30°C at room temperature. Then, samples were incubated with secondary antibodies using Alexa Fluor 488 green or Alexa Fluor-546 red (Life Technologies, Illkrich, France) and Hoechst 33342 for nuclei (Thermo Fisher Scientific) in 10% FBS in PBS for 30 min at room temperature. Coverslips were mounted with Fluoromount-G (SouthernBiotech, Birmingham, AL, USA) and then visualized with Leica TCS SPE confocal microscope (Leica Microsystems, Nanterre, France) using a × 63 objective. In experiments of 53BP1 and γ-H2AX foci visualization in irradiated THP1 cells, Z series of optical sections at 1 μm increments was acquired. In experiments of ATMS1981* and γ-H2AX foci visualization in RAW264.7 cells treated with mIFN-γ, LPS or CDDP, Z series of optical sections at 1.7 μm increments were acquired. In experiments of ATMS1981* and γ-H2AX foci visualization in RAW264.7 cells treated with KU55933 and irradiated, Z series of optical sections at 2.0 μm increments were acquired. For flow cytometry analysis, PMA-differentiated THP1 macrophages were fixed in 4% paraformaldehyde-PBS for 15 min and permeabilized with 0.03% Triton X-100 (Sigma-Aldrich) for 15 min at room temperature. Cells were then blocked with FBS during 1 h at 4°C and incubated as indicated for 30 min at 4°C, with anti-phospho-ATM (Ser1981) (EP1890Y) (#GTX61739, GeneTex, Irvine, CA, USA), anti-phospho-H2AX (Ser139) (#05-636, EMD Millipore) or anti-iNOS (#ab3523, Abcam) antibodies. Then, cells were incubated with the secondary antibodies conjugated to Alexa Fluor 488 fluorochrome (Life Technologies) for 30 min at 4°C and analyzed with Guava flow cytometer (EMD Millipore).
Immunoprecipitation and western blots. Cells were washed twice with cold PBS and lysed with NEHN buffer (0.5% NP40, 20% Glycerol, 300 mM NaCl, 20 mM Hepes, pH 7.5 and 1 mM EDTA) complemented with 2.5 mM DTT, and the protease and phosphatase inhibitor (Roche, Basel, Switzerland) at 4°C. About 5-20 μg of proteins were separated by NuPAGE 4-12% or 10% SDS-PAGE gel (Invitrogen, Illkrich, France), and then were transferred onto a nitrocellulose membrane (0.2 μ, Bio-Rad, Marnes-la-coquette, France). Membranes were blocked with 5% non-fat milk or 5% bovine serum albumin (BSA) in Tris-buffered saline and 0.1% Tween 20 (TBS-T) at room temperature for 1 h and then subsequently probed with primary antibodies overnight at 4°C. Then, membranes were incubated with appropriate horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (SouthernBiotech, Birmingham, AL, USA) for 1 h at room temperature. After three washes with TBS-T, immunoblots were revealed using G:BOX Chemi XL1. 4 Fluorescent & Chemiluminescent Imaging System (Syngene, Cambridge, UK). For immunoprecipitations, 2 Gy-irradiated RAW264.7 cells were harvested and lysed in NEHN buffer. About 2 mg of total lysates were incubated with 2 μg of anti-IRF5 antibodies (#ab21689, Abcam) or with anti-phospho-serine antibodies (#ab9332, Abcam) at 4°C on the wheel for overnight. Then, the immunocomplexes were precipitated with protein G immobilized on sepharose beads for further 4 h at 4°C. After three washings in NEHN buffer containing 300 mM NaCl and one in NEHN buffer with 600 mM NaCl, immunoprecipitates and protein inputs were boiled in the Laemmli buffer (Bio-Rad, Marnes-la-coquette, France) for 10 min at 95°C and analyzed by western blot for the indicated antibodies.
Detection of ROS production. Hydrogen peroxide and anion superoxide production were determined by staining cells with 5 μM of 2,7-dichlorodihydrofluorescein diacetate (H 2 DCFDA, #D6883, Sigma-Aldrich) for 40 min at 37°C. Cells were then washed twice with Hanks' balanced salt solution (HBSS, Thermo Fisher Scientific, Illkrich, France) and suspended in cold HBSS solution containing 1% FBS for FACS analysis.
Determination of LDH release. The release of LDH in the supernatants of cultured cells was detected using Cytotoxicity Detection KitPLUS (LDH, #04744926001) from Roche according to the manufacturer's instructions.
Quantitative RT-PCR. Total RNA of 2 Gy-irradiated PMA-differentiated THP1 macrophages and control cells were purified using RNeasy kit (Qiagen, Hilden, Germany) after 96 h post irradiation according to the manufacturer's instructions. For the detection of cytokine mRNA, the synthesis of cDNA and the quantitative PCR procedure using Syber Green were performed as previously described. 60 The sequences of the primers used are the following: (5′-3′) IL-23 (F:GTTCTGCTT GCAAAGGATCCA, R:TATCCGATCCTAGCAGCTTCTCA), IL-6 (F:GCTGCAGGCAC AGAACCA, R:ACTCCTTAAAGCTGCGCAGAA), TNFα (F:GGAGAAGGGTGACCG ACTCA, R:TGCCCAGACTCGGCAAAG), IFNγ (F:AACTCATCCAAGTGATGGCTG AA, R:CTGACTCCTTTTTCGCTTCCCTG) and HPRT1 (F:GGACAGGACTGAACG TCTTGC, R:CTTGAGCACACAGAGGGCTACA). All samples were normalized with the endogenous hypoxanthine phosphoibosyltransferase 1 (HRPT1) mRNA. For the detection of IRF5 and ATM mRNA, the cDNA synthesis and TaqMan qPCR procedures were performed as previously described. 59 The used probes of IRF5 (Hs 00158114 m1), ATM (Hs01112355 gl) and GAPDH (Hs02758991 gl) were included in the premade TaqMan Gene expression mixes obtained from Applied Biosystems (Foster City, CA, USA). Results were analyzed with the cycle threshold methods (C T ) and each sample was normalized to the quantity of endogenous GAPDH mRNA.
Human cytokine profiling. Human MDMs were irradiated at 4 Gy and were further incubated for 96 h. The supernatants were harvested, centrifuged and stored at − 80°C until use. Human cytokines in these supernatants were measured using the proteome profiler Human cytokine array panel A (proteome profiler, #ARY005, R&D Systems) according to the manufacturer's instructions. Briefly, membranes were blocked with the blocking buffer at room temperature for 1 h. Supernatants of hMDMs were mixed with a biotinylated detection antibody cocktail and then incubated with the membranes overnight at 4°C. Membranes were washed three times for 10 min and subsequently incubated with streptavidin-horseradish peroxidase for 30 min at room temperature. Membranes were then washed three times for 10 min and exposed to peroxidase substrate, and revealed with the G:BOX Chemi XL1.4 Fluorescent and Chemiluminescent Imaging System (Syngene). Time of exposure was between 1 and 10 min. The images were then analyzed using GeneTools software gel image analysis (Syngene).
In vivo mouse tumor model. To generate xenograft tumor model, 4 × 10 6 human colorectal HCT116 cells were inoculated subcutaneously in the flanks of 5-week female nude mice. Two weeks later, the tumors were irradiated at 20 Gy using Variant-NDI-226-n°87262-YO X-Ray Tube. Tumor volume was monitored every 4-5 days. Mice were killed when tumors in the control group exceeded 1000 mm 3 .
Immunohistochemistry. Tumors obtained from in vivo experiments were resected, fixed and embedded in paraffin. Paraffin-embedded tumor samples from rectal patients undergoing neoadjuvant radiotherapy were kindly offered by Dr. Celine Mirjolet in Centre Georges-François Leclerc, Dijon. Frozen tumor samples from rectal patients before and after radiotherapy were obtained from Gustave Roussy Cancer Center. Tumor sections were then dried, deparaffinized and hydrated, followed by antigen retrieval with 0.01 M sodium citrate buffer, pH 6.0 at 97.6°C for 20 min. After washing with TBS-T, slides were blocked with 10% FBS in PBS at room temperature for 1 h. Then primary antibodies diluted in 10% FBS in PBS were applied to each section and incubated overnight in humidified chamber at 4°C. After three washes with TBS-T, Alexa Fluor-conjugated secondary antibodies and Hoechst 33342 diluted in 10% FBS in PBS were applied to each section and incubated for 30 min at room temperature. Then, the slides were washed three times with TBS-T and once with water. Coverslips were mounted on slides using Fluoromount-G medium (SouthernBiotech) before visualization with Leica TCS SPE confocal microscope (Leica Microsystems) using a × 63 objective.
Human samples. Human tissue samples of locally advanced rectal tumors that were resected 42 days after receiving 45 Gy (1.8 Gy/sessions) concomitantly to chemotherapy (5-FU) (n = 4) or left unirradiated (n = 4) were obtained from Gustave Roussy Cancer Campus (Villejuif, France). All tumor samples from responders and non-responders to chemoradiotherapy were obtained from Centre Georges François Leclerc (Dijon, France). This study was approved by the IRB and the French CCTIRS committee (Comité consultatif sur le traitement de l'information en matière de recherche et de santé) and CNIL (Commission nationale de l'informatique et des libertés). Characteristics of these patients are shown in Supplementary Table 1. All these patients (n = 56) were diagnosed for locally advanced rectal tumors and characterized the Tumor Node Metastasis (TNM) classification. All human samples were obtained after approval by the institutional review board and ethics committee, with fully informed consents.
Statistical analysis. Two-way ANOVA test was used to establish statistical differences between the growth of non-irradiated and irradiated tumors in xenografted mice, Mann-Whitney U-test to establish statistical differences in biological activity (iNOS or NOX2 expression) and in phosphorylation (γ-H2AX or ATMS1981*) of macrophages, and in the number of infiltrated CD11b + cells between irradiated and non-irradiated tumors of xenografted mice or between tumors obtained from locally advanced rectal cancer patients who received or not 45 Gy total dose. Multivariate analysis with Wald test was used to determine statistical differences between tumors biopsies obtained from patients with locally advanced rectal tumors that respond or not to chemoradiotherapy. Statistical analysis of in vitro data was performed using Student's t-test or one-way ANOVA test (for Figures 2p,4b, d ,5i, k and Supplementary Figure 2j) . Statistically significant values are reported in figure legends. All experiments were independently performed at least three times. Data are expressed as mean ± S.E.M. GraphPad Prism version 6.0b (GraphPad Software, La Jolla, CA, USA) was employed to perform statistical analysis.
